Radiation-induced organizing pneumonia after stereotactic body radiotherapy for lung tumor

Satoru Ochiai1*, Yoshihito Nomoto2, Yasufumi Yamashita1, Shuuichi Murashima3, Daisuke Hasegawa3, Yusuke Kurobe3, Yutaka Toyomasu2, Tomoko Kawamura2, Akinori Takada2 and Noriko II2

1Department of Radiation Oncology, Matsusaka Central Hospital, 102 Kobou Kawai-machi, Matsusaka, Mie, 515-8566, Japan
2Department of Radiology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan
3Department of Radiology, Matsusaka Central Hospital, 102 Kobou Kawai-machi, Matsusaka, Mie, 515-8566, Japan

*Corresponding author. Department of Radiation Oncology, Matsusaka Central Hospital, 102 Kobou Kawai-machi, Matsusaka, Mie, 515-8566, Japan. Tel: +81-598-21-5252; Fax: +81-598-21-9555; Email: sochiai1981@gmail.com

Received February 6, 2015; Revised June 22, 2015; Accepted July 18, 2015

ABSTRACT

The aim of this retrospective study was to investigate characteristics of organizing pneumonia (OP) after stereotactic body radiotherapy (SBRT) for lung tumor. Between September 2010 and June 2014, patients who were diagnosed as Stage I lung cancer and treated with SBRT at our institution were included in this study. A total of 78 patients (47 males with a median age of 80 years) were analyzed. The median follow-up period was 23 months. Five patients (6.4%) developed OP at 6–18 months after SBRT. The cumulative incidence of OP was 4.3% (95% confidence interval [CI], 1.1–11.0) and 8.2% (95% CI, 2.9–17.0) at 1 and 2 years, respectively. Tumor location (superior and middle lobe vs inferior lobe) was shown to be a borderline significant factor for the occurrence of OP (P = 0.069). In the subgroup analysis of patients with a radiographic follow-up period at least 6 months, or who died within 6 months after SBRT, 7 of 72 patients (9.7%) developed Grade 2 or 3 radiation pneumonitis (G2/3 RP) at 2–4 months after SBRT. A statistically significant association between G2/3 RP in the subacute phase and OP was shown (P = 0.040). In two of the five patients who developed OP, the symptoms and radiographic change were improved rapidly by corticosteroid administration. One patient had relapsed OP after suspending the treatment and re-administration was required. Three patients with minor symptoms were managed without corticosteroid administration and OP resolved without any relapse. The radiation-induced OP should be considered as one of the late lung injuries after SBRT for lung tumors.

KEYWORDS: organizing pneumonia, BOOP syndrome, radiation pneumonitis, stereotactic body radiotherapy, stereotactic ablative radiotherapy, lung cancer, lung tumor

INTRODUCTION

Stereotactic body radiotherapy (SBRT), also called stereotactic ablative radiotherapy (SABR), has been widely used as an effective and safe treatment for early-stage lung cancer, especially in medically inoperable cases [1, 2]. SBRT provides a favorable local control and survival benefit compared with conventional radiotherapy [1–3]. Severe clinical toxicities after SBRT are fairly uncommon for the treatment of peripheral lung tumors, and the rate of Grade 5 complications was reported as 0.6% in the nationwide survey in Japan [4]. Radiation pneumonitis (RP) is one of the most common toxicities after SBRT for lung tumors [1, 2, 5]. Although a few cases were severe and there was a risk of mortality [4, 6, 7], most of the RP was Grade 1 or 2 and either asymptomatic or manageable. The rate of symptomatic RP is typically <10% [5].

Radiation-induced organizing pneumonia (OP), also called bronchiolitis obliterans organizing pneumonia (BOOP), is another lung injury that occurs after thoracic radiotherapy [8–17]. There are several differences between OP and RP. (i) RP occurs during or shortly after the completion of radiotherapy, while OP occurs several months after the completion of radiotherapy; (ii) RP lesions are limited to the irradiated area, while OP lesions are characterized by lung infiltrates outside the radiation field and frequently migrate;
(iii) RP always results in fibrosis and never relapses, while OP usually resolves without fibrosis but commonly relapses when the corticosteroid is withdrawn [14, 15].

Although OP after post-operative radiotherapy (PORT) for breast cancer has been investigated in numerous studies [8–14], there are few reports describing OP after SBRT for lung tumors [16, 17]. This retrospective study was conducted to investigate the characteristics of OP after SBRT for early-stage lung cancer.

**MATERIALS AND METHODS**

**Study design and patient selection**

This single-institutional retrospective study was conducted after approval by our institutional review boards. The necessity for informed consent for inclusion in this study was waived.

Between October 2010 and June 2014, 88 patients with a solitary lung tumor were treated with SBRT at our institutions. Among them, 78 (88.6%) patients had T1N0M0 or T2aN0M0 stage lung cancer according to the 7th edition of UICC TNM staging and were included in this study. They all had a solitary lung tumor of <5 cm, with no evidence of metastases in pretreatment evaluation. Patients who had a tumor that was not confirmed by histology but who had a significant uptake of 18F-fluorodeoxyglucose (FDG) on positron emission tomography (PET) and were diagnosed clinically as having lung cancer by pulmonologists and radiologists were included in this study. Patients who had undergone curative resection of another non-small cell lung cancer (NSCLC) were also included if the target lung tumor was in a lung lobe different from the one that had been treated previously.

Pretreatment evaluation was performed by a routine physical examination, with laboratory tests and imaging studies, including chest radiograph, chest and abdominal computed tomography (CT) with or without contrast-enhanced medium, brain magnetic resonance imaging and FDG PET/CT studies. After January 2011, serum Krebs von den Lungen (KL)-6 level was evaluated routinely, and the pretreatment KL-6 level was available in 71 (91.0%) patients. The characteristics of evaluated patients are shown in Table 1.

SBRT

Our methods for treatment planning have been described in detail previously [18]. The dose fractionation schedule and SBRT parameters are shown in Table 2. SBRT plans were generated using the Pinnacle planning system (Phillips Medical System, Andover, MA). Monitor units were calculated using a collapsed cone convolution algorithm. The clinical target volume was defined as the visible gross tumor volume. The internal target volume (ITV) was chosen considering CT using a slow scan technique. The planning target volume (PTV) was defined as the ITV with a 5-mm margin to allow for set-up uncertainty. A respiration-monitoring apparatus was used for breath-holding conditions if the amplitude of tumor motion was large. In the case of the amplitude of tumor motion being within 1.5 cm in each direction, instead of using the breath-holding technique, the range of the tumor was considered in delineation of ITV. The dose was prescribed to the isocenter. A total dose of 40–60 Gy was administered in 4–10 fractions. We typically prescribed a total dose of 48 Gy in 4 fractions. A prescription of total dose of 52–54 Gy in 4 fractions or 60 Gy in 6 fractions was used in some patients with tumors >3 cm, and of 40 Gy in 4 fractions or 60 Gy in 8–10 fractions in patients who had tumors near critical organs such as the brachial plexus, esophagus or great vessels. The overall treatment time of SBRT ranged from 4 to 12 days in cases of 4 fractions and from 9 to 18 days in cases of 6–10 fractions. The total lung volume covered with 20 Gy or more (Lung V20) and the mean lung dose (MLD) were evaluated on the treatment planning workstation. Irradiation

| Variables | No. of patients (%) |
|-----------|---------------------|
| Age       | median age (years) (range) | 80 (46–91) |
| Sex       | male | 47 (60.3) |
|           | female | 31 (39.7) |
| Emphysematous change in lung | yes | 39 (50.0) |
|           | no | 39 (50.0) |
| Serum KL-6 level | median (U/ml) (range) | 285 (109–711) |
| Tumor size | median (mm) (range) | 22 (8–45) |
| Tumor location in lung | superior or middle lobe | 46 (61.5) |
|           | inferior lobe | 30 (38.5) |

*Pretreatment serum KL-6 was available in 71 (91.0%) patients. KL-6 = Krebs von den Lungen-6.

Table 2. Dose fractionation and SBRT parameters

| Dose fractionation, Gy/Fractions | No. of patients (%) |
|---------------------------------|---------------------|
| 40/4                            | 2 (2.6) |
| 48/4                            | 58 (74.4) |
| 52/4                            | 3 (3.8) |
| 54/4                            | 1 (1.3) |
| 60/6                            | 2 (2.6) |
| 60/8                            | 11 (14.1) |
| 60/10                           | 1 (1.3) |
| Median total dose (Gy) (range) | 48 (40–60) |
| Median dose per fraction (Gy) (range) | 12.0 (6.0–13.5) |
| Median number of fractions (range) | 4 (4–10) |
| Median overall treatment time (days) (range) | 5 (4–18) |
| Median lung V20 (%) (range) | 6.3 (2.4–14.7) |
| Median mean lung dose (Gy) (range) | 4.0 (2.1–10.1) |

Lung V20 = lung volume covered with 20 Gy or more.
Diagnosis of OP after SBRT

The criteria for the diagnosis of OP after SBRT were defined by reference to previous criteria for SBRT of the lung and PORT for breast cancer [8–16]: (i) a mixture of patchy and ground-glass opacity, (ii) general and/or respiratory symptoms lasting for at least 2 weeks, (iii) synchronous or metachronous (migrated) radiographic lesion in the lung volume receiving <0.5 Gy, and (iv) no evidence of a specific cause. The diagnosis was determined by three radiation oncologists (S.O., Y.Y. and Y.N.) and three radiologists (S.M., D.H. and Y.K).

Follow-up studies

Patients were followed until February 2015 or death. CT scans were performed every 3 months until 2 years after the treatment and were repeated every 4–6 months thereafter. Toxicities of SBRT were evaluated using the Common Terminology Criteria for Adverse Events Version 4. The follow-up period after SBRT ranged from 0 to 63 months (median, 23 months).

Statistical analysis

The main endpoint of this study was the incidence of OP after SBRT. The endpoint was calculated from the first day of SBRT. The cumulative incidence of OP was calculated by accounting for death as a competing risk [19, 20]. To investigate the risk factor for development of OP, the incidence of OP was first compared using Gray’s test between the following covariates: age, sex, pretreatment serum KL-6 level, prior surgery for another lung cancer, tumor size, emphysema-tous change in lung, tumor location, total dose of SBRT, dose per fraction, number of fractions, overall treatment time, MLD and Lung V20 [21]. The threshold values for Gray’s test were medians in variables. The threshold of the serum KL-6 level was also selected as the median in this study. Although the cut-off level in the diagnosis of interstitial pneumonia is 500 U/ml, the optimal cut-off level as a predictor of lung injury after radiation therapy is still under debate [22]. Spearman’s rank correlation coefficient was used to evaluate the relationship between variables.

Second, we conducted a subgroup analysis of patients with a radiologic follow-up period at least 6 months or who died within 6 months after SBRT (72/78, 92.3%) to evaluate the OP as a late adverse event after SBRT. In this analysis, the cumulative incidence of Grade 2 or 3 RP (G2/3 RP) was also calculated. We evaluated the impact of G2/3 RP within 6 months (subacute phase) on the occurrence of OP with a landmark method [16, 23]. A P-value of <0.05 was inferred as statistically significant. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, The R Foundation for Statistical Computing) [24].

RESULTS

The incidence of OP

Five patients developed OP after SBRT during the follow-up and the crude incidence was 6.4% (5/78). The development of OP was observed at 6–18 months after SBRT. Of 78 patients, 10 (12.8%) had died by the end of follow-up. The cumulative incidence of OP was 4.3% (95% confidence interval (CI), 1.1–11.0) and 8.2% (95% CI: 2.9–17.0) at 1 year and 2 years, respectively (Fig. 1).

Clinical course and characteristics of OP patients

The clinical course and characteristics of OP are summarized in Table 3. An example of OP is shown in Fig. 2. Four males and one female developed OP, and the age ranged from 70 to 85 years old. The irradiated dose was 48 Gy in four fractions in three patients and 60 Gy in eight fractions in another two patients. G2/3 RP was observed in two patients before the development of OP. Two patients had major (Grade 2) symptoms. They were administered with corticosteroid as an initial treatment for OP, and symptoms and radiographic change improved rapidly. Relapse of OP was observed in one patient after suspending corticosteroid administration, and re-administration of corticosteroid was required. Corticosteroids to the two patients were being tapered at the time of the analysis. The other three patients with minor symptoms (Grade 1) were managed without corticosteroid treatment and the symptoms and the radiographic change were resolved within 3–6 months after diagnosis. No relapse was observed in these patients during the follow-up.

Risk factor analysis of OP after SBRT

The result of Gray’s test is summarized in Table 4. No statistically significant factor for occurrence of OP was detected in this analysis. Tumor location (superior/middle lobe vs inferior lobe) was shown to be a borderline statistically significant factor (P = 0.069). There was no significant correlation between tumor location and other variables. The number of fractions (4 fractions vs >4 fractions) had a trend
toward significance (P = 0.112). There were very strong correlations between number of fractions and total dose (ρ = 0.854, P < 0.001) and dose per fraction (ρ = −0.864, P < 0.001). There was moderate correlation between number of fractions and overall treatment time (ρ = 0.576, P < 0.001). Although OP was not observed in patients with prior surgery for another cancer, this factor was not statistically significant (P = 0.215).

Relationship between G2/3 RP in subacute phase and OP
Of the 78 patients, 72 (92.3%) were followed up radiologically for at least 6 months or died within 6 months after SBRT. These patients were analyzed for OP as a late adverse event after SBRT. Among them, 7 patients (9.6%) developed Grade 2/3 OP after SBRT. Of these, Grade 3 RP occurred in 1 patient and the others had Grade 2 RP. G2/3 RP developed at 2–4 months (subacute phase) after SBRT, and the cumulative incidence of G2/3 RP was 9.7% (95% CI, 4.2–17.9) at 6 months. No statistically significant factor for developing G2/3 RP was found in Gray’s test in this subgroup. G2/3 RP in the subacute phase was shown to be a statistically significant risk factor for development of OP, using a landmark method (P = 0.040) (Fig. 3). The 1-year and 2-year cumulative incidence was 14.3% and 28.6% in patients with prior G2/3 RP and 3.1% and 5.4% in patients without G2/3 RP, respectively (Fig. 3).

DISCUSSION
In this study, we retrospectively analyzed the OP after SBRT for early-stage lung cancer and described the characteristics of OP. Although numerous studies have been reported for OP after PORT for breast cancer [8–15], there are few reports describing OP after SBRT for lung tumors [16, 17]. Table 5 summarizes the reported results of OP after PORT for breast cancer and after SBRT of the lung.

| No. | Sex | Age | Dose/Fx | RP | Symptoms of OP | Tx | Clinical course |
|-----|-----|-----|---------|----|----------------|----|----------------|
|     |     |     |         |    | Fever Fatigue  | Cough  | Dyspnea |     |               |
| 1   | M   | 74  | 48/4    | Yes| 0 1 1 1       | Obs  | Resolved      |
| 2   | M   | 70  | 60/8    | No | 1 1 0 1       | Obs  | Resolved      |
| 3   | M   | 85  | 48/4    | Yes| 1 2 1 2       | PSL  | Relapse after remission |
| 4   | M   | 79  | 60/8    | No | 1 2 0 2       | PSL + Abx | Remission |
| 5   | F   | 74  | 48/4    | No | 0 0 1 1       | Abx  | Resolved      |

Fx = fractions, RP = Grade 2 or 3 radiation pneumonitis, OP = organizing pneumonia, Tx = treatment, M = male, F = female, Obs = observation, PSL = prednisolone, Abx = antibiotics.

Table 3. The summary of clinical characteristics and course of OP

Fig. 2. Chest CT and dose distribution of stereotactic body radiotherapy (SBRT) of a 70-year-old male patient. Dose distribution of SBRT. Isodose lines of 60 Gy (blue), 50 Gy (green), 40 Gy (purple), 30 Gy (light blue), 20 Gy (lavender) and 0.5 Gy (yellow) (A, B). Radiation pneumonitis (RP) represents in high-dose irradiated area (C, orange arrow) and patchy opacity in left lung appeared 6 months after SBRT (D, red arrow). No significant change in RP 9 months after SBRT (E, orange arrow). The radiographic lesion in the left lung disappeared and a new lesion in the right lung appeared. (F, red arrow). These radiographic changes were considered to be the sequential change of organizing pneumonia (OP) (migration). RP resulted in fibrosis (G, orange arrow), and OP resolved without fibrosis at 12 months after SBRT (H).
In our series, OP occurred in 5 out of 78 (6.4%) patients after SBRT, and the cumulative incidence of OP was 4.3% and 8.2% at 1 year and 2 years, respectively. Murai et al. reported OP after SBRT for primary or metastatic lung cancer [16]. They reported that the crude incidence of OP was 4.8% (9/189) and the cumulative incidence was 4.0% and 5.2% at 1 year and 2 years, respectively. Our incidence of OP was similar to their results. The incidence of OP after PORT for breast cancer has been reported to be ∼2% [8–15]. The incidence of OP after SBRT of the lung seemed to be high compared with that after PORT for breast cancer.

The interval from SBRT to development of OP ranged from 6 to 18 months in our study. Murai et al. reported that the interval ranged from 6 to 16 months [16]. Our results were quite similar to theirs. Takeda et al. also reported one case of OP in their prospective trial of SBRT, and it occurred at 6 months after SBRT [17]. It has been reported that most occurrences of OP after breast irradiation develop within 6 months [8–15]. The latency period for development of OP after SBRT is relatively long compared with that of PORT for breast cancer. This might be affected by the differing lengths of overall treatment time.

There are several differences between OP and RP. (i) RP occurs during or shortly after the completion of radiotherapy, whereas OP occurs several months after completion of radiotherapy; (ii) RP lesions are limited to the irradiated area, whereas OP lesions are characterized by lung infiltrates outside the radiation field and frequently migrate; (iii) RP always results in fibrosis and never relapses, whereas OP usually resolves without fibrosis but commonly relapses when the corticosteroid is withdrawn [14, 15]. While RP is known to be a direct effect of irradiation, the underlying mechanism that develops radiation-induced OP remains unclear. An autoimmune process is assumed to be at the base of the development of OP. Irradiation provokes tissue damage via sensitization of autoreactive lymphocytes, which react with pulmonary tissue [25]. Thus, OP is clearly different.

### Table 4. The results of Gray’s test

| Variables                   | No. of patients (%) | 2-year cumulative incidence of OP | P value  |
|-----------------------------|---------------------|----------------------------------|----------|
| Age                        |                     |                                  |          |
| ≤80 years                   | 40 (51.3)           | 11.5                             | 0.288    |
| >80 years                   | 38 (48.7)           | 3.6                              |          |
| Sex                        |                     |                                  |          |
| Male                       | 47 (60.3)           | 12.7                             | 0.259    |
| Female                     | 31 (39.7)           | 3.3                              |          |
| Prior surgery               |                     |                                  |          |
| Yes                        | 19 (24.4)           | 0.0                              | 0.215    |
| No                         | 59 (75.6)           | 10.5                             |          |
| serum KL-6 level            |                     |                                  |          |
| ≤285 U/ml                  | 35 (49.3)           | 6.3                              | 0.057    |
| >285 U/ml                  | 36 (50.7)           | 12.8                             |          |
| Emphysematous change        |                     |                                  |          |
| Yes                        | 39 (50.0)           | 8.3                              | 0.667    |
| No                         | 39 (50.0)           | 8.6                              |          |
| Tumor size                  |                     |                                  |          |
| ≤22 mm                     | 37 (47.4)           | 5.9                              | 0.688    |
| >22 mm                     | 41 (52.6)           | 11.2                             |          |
| Tumor location              |                     |                                  |          |
| Sup or mid                 | 48 (61.5)           | 13.4                             | 0.069    |
| Inf                        |                     |                                  |          |
| Total dose                  |                     |                                  |          |
| ≤48 Gy                     | 60 (76.9)           | 6.0                              | 0.202    |
| >48 Gy                     | 18 (23.1)           | 17.3                             |          |
| Dose per fraction           |                     |                                  |          |
| <12 Gy                     | 16 (20.5)           | 16.8                             | 0.232    |
| ≥12 Gy                     | 62 (79.5)           | 6.0                              |          |
| Number of fractions         |                     |                                  |          |
| 4                          | 64 (82.1)           | 5.8                              | 0.112    |
| >4                         | 14 (17.9)           | 20.5                             |          |
| Overall treatment time      |                     |                                  |          |
| ≤5 days                    | 47 (60.3)           | 7.6                              | 0.809    |
| >5 days                    | 31 (39.7)           | 9.9                              |          |
| Mean lung dose              |                     |                                  |          |
| ≤4.0 Gy                    | 39 (50.0)           | 6.5                              | 0.661    |
| >4.0 Gy                    | 39 (50.0)           | 9.7                              |          |
| Lung V20                    |                     |                                  |          |
| ≤6.2%                      | 39 (50.0)           | 6.4                              | 0.622    |
| >6.2%                      | 39 (50.0)           | 9.9                              |          |

OP = organizing pneumonia, Prior surgery = prior surgery for another lung cancer, KL-6 = Krebs von den Lungen-6, Sup = Superior lobe, Mid = middle lobe, Inf = inferior lobe, Lung V20 = lung volume covered with 20 Gy or more. *Pretreatment serum KL-6 level was available in 71 (91.0%) patients.

In our series, OP occurred in 5 out of 78 (6.4%) patients after SBRT, and the cumulative incidence of OP was 4.3% and 8.2% at 1 year and 2 years, respectively. Murai et al. reported OP after SBRT for primary or metastatic lung cancer [16]. They reported that the crude incidence of OP was 4.8% (9/189) and the cumulative incidence was 4.0% and 5.2% at 1 year and 2 years, respectively. Our incidence of OP was similar to their results. The incidence of OP after PORT for breast cancer has been reported to be ∼2% [8–15]. The incidence of OP after SBRT of the lung seemed to be high compared with that after PORT for breast cancer.

The interval from SBRT to development of OP ranged from 6 to 18 months in our study. Murai et al. reported that the interval ranged from 6 to 16 months [16]. Our results were quite similar to theirs. Takeda et al. also reported one case of OP in their prospective trial of SBRT, and it occurred at 6 months after SBRT [17]. It has been reported that most occurrences of OP after breast irradiation develop within 6 months [8–15]. The latency period for development of OP after SBRT is relatively long compared with that of PORT for breast cancer. This might be affected by the differing lengths of overall treatment time.

There are several differences between OP and RP. (i) RP occurs during or shortly after the completion of radiotherapy, whereas OP occurs several months after completion of radiotherapy; (ii) RP lesions are limited to the irradiated area, whereas OP lesions are characterized by lung infiltrates outside the radiation field and frequently migrate; (iii) RP always results in fibrosis and never relapses, whereas OP usually resolves without fibrosis but commonly relapses when the corticosteroid is withdrawn [14, 15]. While RP is known to be a direct effect of irradiation, the underlying mechanism that develops radiation-induced OP remains unclear. An autoimmune process is assumed to be at the base of the development of OP. Irradiation provokes tissue damage via sensitization of autoreactive lymphocytes, which react with pulmonary tissue [25]. Thus, OP is clearly different.

![Fig. 3. Comparison of the cumulative incidence of organizing pneumonia (OP) of patients with or without Grade 2 or 3 radiation pneumonitis (G2/3 RP) within the subacute phase with landmark method. G2/3 RP 2 in subacute phase was shown to be a significant risk factor for development of OP, compared with those without G2/3 RP (Gray’s test \( P = 0.040 \)).](image-url)
from RP. However, it has been reported that there is close relationship between RP and OP after PORT for breast cancer [12, 14]. Murai et al. reported that most OP occurred a few months after RP, and that there was a very strong association between prior symptomatic RP and OP after SBRT of the lung [16]. We also found a statistically significant correlation between G2/3 RP and the development of OP in the subgroup analysis of patients with at least 6 months of follow-up period. Our results support their findings, and there could be a close relationship between OP and RP after SBRT for lung tumor as well as PORT for breast cancer. We evaluated MLD and Lung V20 as parameters for risk assessment of RP during treatment planning. After January 2010, pre-treatment KL-6 was routinely evaluated. Although these have been reported as predictive factors for the development of RP [5, 21, 26–28], no direct relationship between these factors and OP was shown in this analysis.

In our series, tumor location (superior/middle lobe vs inferior lobe) was shown to be a borderline statistically significant factor. Indeed, only patients with tumors in the superior lobe developed OP in our cohort. This result might indicate that the region where the RP occurs is the factor for developing OP. The pleural factor was indicated as the key to understanding the development of OP after PORT for breast cancer in some reports [8, 29]. With PORT for early-breast cancer, tangential fields are used to limit the dose given to the lung in order to reduce the incidence of RP. Tangential fields mainly induce an irradiation of subpleural regions of the lung. Cresciani et al. reported that infiltrates of OP after PORT for breast cancer began in the irradiated area then spread to non-irradiated areas of the ipsilateral lung [8]. Oie et al. reported an imaging study with CT and that most OP lesions developed in close proximity to the RP lesions [14]. According to these findings, it seems that the damage to subpleural region of the lung and pleura could be the primer for OP. In SBRT, lung tumor is irradiated with multiple non-coplanar beams in fewer fractions. As a result, relatively extensive subpleural region of lung or pleura could be irradiated by a high biological effective dose just like PORT for breast cancer. 50 Gy in 25 fractions approximately equivalent to 26 Gy in 4 frs or 38 Gy in 8 fractions using the linear quadratic model, with an alpha/beta ratio of 3 Gy (Fig. 4).

The number of fractions (4 fractions vs >4 fractions) also had a trend toward significance in our analysis. However, this was considered to be a confounding factor. Tumors near the brachial plexus tended to be irradiated in larger number of fractions at our institution.

The optimal management of radiation-induced OP is still controversial [8–16, 30–32]. OP may be monitored if symptoms are minimal [32]. The effectiveness of macrolide antibiotics for OP has been reported [11, 30–32]. If OP worsens, corticosteroid administration can be applied. It provides rapid improvement of symptoms and radiographic change in most patients. Although relapse of OP is not rare after suspending the treatment or while the corticosteroids are tapered, administration of the least amount for the shortest possible period of time is preferable [30–32].

Two patients who developed OP with major symptoms were treated with corticosteroids as the initial treatment for OP in our series. Symptoms and radiographic change improved rapidly in these patients. However, OP relapsed in one patient after suspending administration of corticosteroid and re-administration was required. The other three patients, with minor symptoms, were managed without corticosteroid treatment. The symptoms and the radiographic change in these patients were resolved within 6 months and no relapse was observed during the follow-up. These results were similar to OP after PORT for breast cancer and indicated that the management of OP after PORT for breast cancer could be applied to OP after SBRT for lung tumors.

The retrospective nature of this study is an important study limitation. Lack of histological evaluation also poses a limitation. The diagnoses of OP were determined based only on clinical course and radiological findings; it is possible that we did not exclude other disorders, such as pulmonary infectious disease, from OP. The relatively small cohort size is another limitation. Despite these study limitations, the results of this study contribute to our knowledge of OP after SBRT for lung tumors. Evaluation in large-scale and prospective studies are warranted to confirm our findings.

Table 5. Reported results of OP after PORT for breast cancer and SBRT.

| Series                  | Material                     | No. of Pts | Crude incidence (%) | Latency period range (months) | Related factor                        |
|-------------------------|------------------------------|------------|---------------------|-----------------------------|---------------------------------------|
| Takigawa et al. [10]    | PORT for breast cancer       | 157        | 2.5                 | 5–6                         | Immunologic reaction                 |
| Miwa et al. [25]        | PORT for breast cancer       | 206        | 2.4                 | 2–7                         | Not evaluated                         |
| Ogo et al. [12]         | PORT for breast cancer       | 2056       | 2.4                 | 0–10.5 (mean 4.2)            | No significant factor                 |
| Katayama et al. [13]    | PORT for breast cancer       | 702        | 2.3                 | 2.3–7.9 (median 3.8)         | Age >50 Endocrine therapy             |
|                         |                              |            |                     |                             | Irradiated lung volume                |
| Ogo et al. [11]         | PORT for breast cancer       | 616        | 1.9                 | 3–12 (mean 5.6)              | No significant factor                 |
| Oie et al. [14]         | PORT for breast cancer       | 428        | 1.2                 | 5.6–7.6 (median 7.3)         | RP                                    |
| Murai et al. [16]       | SBRT                         | 189        | 4.8                 | 6–16                        | Symptomatic RP                       |
| This study              | SBRT                         | 78         | 6.4                 | 6–18                        | Grade 2 or 3 RP (Superior lobe of lung) |

PORT = postoperative radiotherapy, SBRT = stereotactic body radiotherapy, RP = radiation pneumonitis.
In conclusion, we have described the characteristics of OP after SBRT for lung tumors. The incidence is relatively high, especially in patients with prior G2/3 RP. The tumor location in the lung might affect the likelihood of development of OP. The latency period for OP is relatively long, and OP could be considered a late adverse event after SBRT. Our findings suggest that long-term and close follow-up is required after SBRT for lung tumors.

ACKNOWLEDGEMENTS
A report on a case of OP after SBRT included in this analysis was presented at the 47th Autumn Assembly of the Japan Radiological Society, Shimonoseki, 21–23 October 2011. Reports on two cases included in this analysis were presented at the 18th Workshop of the Mie Lung Cancer Study Group, Tsu, 21 June 2014. The results of this study were presented at the 28th Annual Meeting of the Japan 3-D Conformal External Beam Radiotherapy Group, Kyoto, 30 May 2015.

FUNDING
Funding to pay the Open Access publication charges for this article was provided by Matsusaka Central Hospital.

REFERENCES
1. Nagata Y. Stereotactic body radiotherapy for early stage lung cancer. Cancer Res Treat 2013;45:155–61.
2. Onishi H, Araki T. Stereotactic body radiation therapy for stage I non-small-cell lung cancer: a historical overview of clinical studies. Jpn J Clin Oncol 2013;43:345–50.
3. Grutters JP, Kessels AG, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 2010;95:32–40.
4. Nagata Y, Hiraoka M, Mizowaki T, et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys 2009;75:343–7.
5. Yamashita H, Takahashi W, Haga A, et al. Radiation pneumonitis after stereotactic radiation therapy for lung cancer. World J Radiol 2014;6:708–15.
6. Takeda A, Enomoto T, Sanuki N, et al. Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing. Radiat Med 2008;26:504–7.
7. Yamashita H, Nakagawa K, Nakamura N, et al. Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after
stereotactic radiation therapy for lung tumors. *Radiat Oncol* 2007;2:21–32.
8. Crestani B, Valeyre D, Roden S, et al. Bronchiolitis obliterans organizing pneumonia syndrome primed by radiation therapy to the breast. *The Group d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires (GERM’O’P).* *Am J Respir Crit Care Med* 1998;158:1929–35.
9. Kubo A, Osaki K, Kawanaka T, et al. Risk factors for radiation pneumonitis caused by whole breast irradiation following breast-conserving surgery. *J Med Invest* 2009;56:99–110.
10. Takigawa N, Segawa Y, Saeki T, et al. Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: radiation-induced lung toxicity. *Int J Radiat Oncol Biol Phys* 2000;48:751–5.
11. Ogo E, Komaki R, Abe T, et al. The clinical characteristics and non-steroidal treatment for radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy. *Radiother Oncol* 2010;97:95–100.
12. Ogo E, Komaki R, Fujimoto K, et al. A survey of radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy in Japan. *Int J Radiat Oncol Biol Phys* 2008;71:123–31.
13. Katayama N, Sato S, Katsui K, et al. Analysis of factors associated with radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy. *Int J Radiat Oncol Biol Phys* 2009;73:1049–54.
14. Irie Y, Saito Y, Kato M, et al. Relationship between radiation pneumonitis and organizing pneumonia after radiotherapy for breast cancer. *Radiother Oncol* 2013;8:56.
15. Epler GR, Kelly EM. Systematic review of postradiotherapy bronchiolitis obliterans organizing pneumonia in women with breast cancer. *Oncologist* 2014;19:1216–26.
16. Murai T, Shibamoto Y, Nishiyama T, et al. Organizing pneumonia after stereotactic ablative radiotherapy of the lung. *Radiat Oncol* 2012;7:123.
17. Takeda A, Oku Y, Sanuki N, et al. Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume. *J Radiat Res* 2014;55:988–95.
18. Ochiai S, Yamakado K, Kodama H, et al. Comparison of therapeutic results from radiofrequency ablation and stereotactic body radiotherapy in solitary lung tumors measuring 5 cm or smaller. *Int J Clin Oncol* 2014;20:499–507.
19. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using *R*: an in depth guide for clinicians. *Bone Marrow Transplant* 2014;46:1388–95.
20. Scrucca L, Santucci A, Aversa F. Competing risk analysis using *R*: an easy guide for clinicians. *Bone Marrow Transplant* 2007;40:381–7.
21. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of competing risk. *Ann Statist* 1998;16:1141–54.
22. Iwata H, Shibamoto Y, Baba F, et al. Correlation between the serum KL-6 level and the grade of radiation pneumonitis after stereotactic body radiotherapy for stage I lung cancer or small lung metastasis. *Radiother Oncol* 2011;101:267–70.
23. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. *J Clin Oncol* 1983;1:710–9.
24. Kanda Y. Investigation of the freely available easy-to-use software ‘EZIR’ for medical statistics. *Bone Marrow Transplant* 2013;48:452–8.
25. Miwa S, Morita S, Suda T, et al. The incidence and clinical characteristics of bronchiolitis obliterans organizing pneumonia syndrome after radiation therapy for breast cancer. *Sarcoidosis Vasc Diffuse Lung Dis* 2004;21:212–8.
26. Yamashita H, Kobayashi-Shibata S, Terahara A, et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. *Radiother Oncol* 2010;5:32.
27. Barriger RB, Forquer JA, Brabham JG, et al. A dose–volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys* 2012;82:457–62.
28. Baker R, Han G, Sarangkasi S, et al. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. *Int J Radiat Oncol Biol Phys* 2013;85:190–5.
29. Cordier JF. Cryptogenic organising pneumonia. *Eur Respir J* 2006;28:422–46.
30. Stover DE, Mangino D. Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia? *Chest* 2005;128:3611–7.
31. Otani K, Nishiyama K, Ito Y, et al. Steroid treatment increases the risk of recurrence of radiation-induced organizing pneumonia after breast-conserving therapy. *Cancer Med* 2014;3:947–53.
32. Epler GR. Post-breast cancer radiotherapy bronchiolitis obliterans organizing pneumonia. *Expert Rev Respir Med* 2013;7:109–12.